BALTIMORE, July 9, 2018 – Elixirgen Therapeutics, Inc. raised $4 million in a Series A funding round from University of Tokyo Edge Capital (UTEC). Elixirgen Therapeutics, Inc. is a biotechnology company founded by Minoru Ko, M.D., Ph.D., that is focused on curing humanity’s ailments through innovations in stem cell biology. Elixirgen Therapeutics is pursuing cures […]

BALTIMORE, May 7, 2018 – Elixirgen Therapeutics, LLC has now incorporated to become Elixirgen Therapeutics, Inc. This change makes the company a better target for investment from strategic partners or venture capital, which will in turn help the company to further its goals in developing and commercializing its therapies.

BALTIMORE, May 30, 2017 – Elixirgen Therapeutics has successfully concluded its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for inherited bone marrow failure syndromes (IBMFS), including Dyskeratosis Congenita (DC) and Fanconi Anemia (FA).